Mammalian cells of both neoplastic and normal origin are more sensitive to most anticancer agents when actively progressing through the cell cycle than when they enter a non-cycling state (van Putten, 1974; Valeriote & van Putten, 1975; Tannock, 1978) . Such cycle selectivity may limit the chemotherapeutic sensitivity of solid tumours, many of which contain a high proportion of non-cycling tumour cells (Steel, 1977; Tannock, 1978) . A deeper understanding of the relationship between proliferative activity and drug sensitivity is needed to clarify the importance of this selectivity in vivo.
Since Bruce and his associates (reviewed by Valeriote & van Putten, 1975; van Putten, 1974) first demonstrated the importance of proliferative state in relation to drug sensitivity in vivo, most studies have utilized in vitro models of non-cycling cells such as plateau-phase cultures (Barranco & Novak, 1974; Drewinko et al., 1981; Hahn & Little, 1972; Twentyman & Bleehen, 1975) and multicellular spheroids (Sutherland & Durand, 1984; Nederman & Twentyman, 1984; Kwok & Twentyman, 1985) . The question remains as to whether these provide adequate models for non-cycling cells in tumours (Valeriote & van Putten, 1975; Twentyman & Bleehen, 1975 ). In the work described here a novel and complementary approach has been adopted by investigating changes in drug sensitivity in short-term primary cultures derived from an advanced murine solid tumour. These cultures initially contain high proportions of cells which have entered a non-cycling state in the tumour, and are then recruited into cycle by growth in culture at low density. The attendant changes in drug sensitivity are compared with those accompanying the progression of exponential-phase cultures into plateau-phase.
Important differences in drug sensitivity between cycling and non-cycling cells have been demonstrated with antimetabolites, alkylating agents and DNA intercalating drugs (Barranco & Novak, 1974; Drewinko et al., 1981; Kwok & Twentyman, 1985; Twentyman & Bleehen, 1975) . The present study focuses on 4-methyl-5-(N-methyl)carboxamideamsacrine (CI-921), a new 9-anilinoacridine derivative which has recently entered phase I clinical trials (Baguley et 1984). This intercalating agent is an analogue of the antileukaemic drug amsacrine, but shows higher activity against a variety of solid tumours in mice including the Lewis lung (LL) carcinoma (Baguley et al., 1984) .
The marked cycle selectivity of amsacrine has been demonstrated in several experimental systems (Drewinko et al., 1981; Wilson et al., 1981a,b) , and its lack of activity against non-cycling cells has been suggested as a reason for its failure to act against solid tumours (Wilson et al., 1981a,b) . It was thus of interest to determine whether the improved activity of CI-921 against a solid tumour is a consequence of a reduced resistance of non-cycling cells to this agent. This paper also describes the cycle selectivity of another clinical intercalating agent, doxorubicin, and that of three alkylating agents of the nitrogen mustard class (nitrogen mustard, cyclophosphamide and chlorambucil).
The cell line studied is a Lewis lung carcinoma subline, designated LLTC, which has been adapted to growth in vitro. When inoculated s.c. into mice, the resulting tumours demonstrate a low growth fraction, and are markedly less drug-sensitive than the parent transplanted Lewis lung line (Baguley et al., 1986 Begg et al. (1985) . Briefly, cyclophosphamide in saline was inoculated i.p. into B6D2F1 mice (60mg ml-1, 0.2 ml per mouse). After 20min, treated and control mice were etheranaesthetized, and blood collected by exsanguination into heparinized pipettes. Plasma was recovered by centrifugation (13,000g for 3min), diluted to 10% v/v in alpha-modified minimal essential medium (MEM), filter-sterilized (0.2Mm pore size), rapidly frozen and stored at -70°C for use 1 and 2 days later.
Tumour cells A Lewis lung tissue culture (LLTC) line, developed from the Lewis lung tumour at the Southern Research Institute, Birmingham, Alabama, USA, (Wilkoff et al., 1980) was obtained from Dr R.C. Jackson (Warner-Lambert Company, Ann Arbor, Michigan, USA) in 1981. LLTC cells were cultured in 25 cm2 plastic flasks using growth medium (GM) consisting of alpha-modified MEM supplemented with foetal bovine serum (FBS, Smith Biolab, New Zealand) and antibiotics (penicillin 100 U ml-1, streptomycin 100 g ml-1).
In early experiments cells were cultured in FBS at 10% (V/v); this was later reduced to 5% (Figure 4 and subsequent clonogenicity assays). In order to propagate LLTC cells for injection into B6D2F1 mice, cultures were established at 104 cellsml-1 in 100mm dishes containing GM (15ml). Cells were grown to at least 1.5 x 107/dish, removed from the plastic using trypsin (0.1%, Difco) in citrate saline (trisodium citrate dihydrate 4.4 g 1-1, KC1 10 g 1-1, pH 7.3), collected by centrifugation, and 106 cells (0.1 ml) injected s.c.
Exponential and plateau-phase LLTC cultures LLTC cultures (1 ml) were initiated in 24-well culture dishes in GM at densities ranging from 104 to 3 x 105 cellsml-1. After growth at 37°C in a CO2 incubator for 66h the cell density, proliferative activity, clonogenicity and drug sensitivity of these cultures were assessed. The 24-well dishes were placed on a temperature block to maintain the cultures at 35-37°C during subsequent manipulations. Culture medium (0.5ml) was discarded from each well, and replaced with 0.5ml of fresh, prewarmed GM containing amsacrine (final concentration SpM), [3 H]-thymidine (2 MCi ml-1) or colchicine (1 Mg ml -1) as required. The dishes were then incubated at 37°C on a grid submerged in a waterbath, under an atmosphere of 5% CO2 in air maintained by flushing the gas mixture through a dome over the cultures at a rate of 81 min-1. After one hour (2 h in the case of colchicine treatment) the cultures were washed with PBS (NaCl 8 g 1-1, KCI 0.2 g 1-1, anhydrous Na2HP04 1.15gl-1, anhydrous KH2PO4 0.2gl-1, CaCl2 0.1gl-1, MgCl.6H2O 0.1 g -1, pH 7.4) and trypsinized. Cell densities were determined with a Coulter counter, and clonogenicity was assessed by plating known numbers of cells (102-104) in GM (5ml) in 60mm tissue culture dishes. After growth for 10 days, colonies were fixed and stained in methylene blue (0.5% w/v in 50% aqueous ethanol). Colonies containing more than 100 cells were counted.
The mitotic index was determined by pooling the PBS wash and trypsinized cells from colchicine-treated cultures, collecting the cells by centrifugation and dropping hypotonically-swollen (0.075M KCI, 37°C, 6min) cells on to microscope slides after fixation with Carnoy's fixative (methanol: acetic acid, 3:1, v/v) Tumour disaggregation
Mice were killed by cervical dislocation and the tumours excised and minced using crossed scalpels. The mince was placed in a glass vessel containing a small spin bar and incubated with stirring in GM (60mg tumour mince ml-') containing pronase (1 mg ml-1) at 37°C for 40min. At the conclusion of the digestion, large aggregates were allowed to settle, most of the supernatant was removed, the cells recovered by centrifugation, and washed once with GM. Large, refractile cells. were counted using a haemocytometer. Recoveries were 1-2 x 108 cells g'-I tumour.
Cell culture and cytotoxicity assays with cells from tumours LLTC cells obtained from tumours had different growth requirements from LLTC cells maintained continuously in culture, in that they required reduced°2 concentrations and high cell densities (or irradiated feeders). Freshly prepared tumour cell suspensions were cultured for one or 4 days by seeding at 105 or 104 cellsml-l respectively and growing in an atmosphere of 5% 02 and 5% CO2 in nitrogen. Drug sensitivity was evaluated by exposing single cell suspensions (pronase digests of tumours or trypsinized day 1 or day 4 cultures) for 1 h in polystyrene tubes as above. Clonogenicity was determined by a modification of a previously described technique (Courtenay, 1976) in which colonies were grown on the substrate in 60mm dishes in liquid culture, rather than in agar. 102-105 cells were plated in each dish with lethally irradiated (35Gy, Cobalt-60) LLTC cells added as feeders to maintain a constant cell number of 105 cells/dish. After growth in an atmosphere of 5% 02 and 5% CO2 for 10 days, colonies were stained with methylene blue and counted as above.
Flow cytometry
Flow cytometry was performed as described previously (Baguley et al., 1984) using the method of Taylor (1980) . Tumours were disaggregated with pronase as above, but the cell suspension was washed twice. Cell suspensions (106 ml-1) were permeabilized by addition of an equal volume of 0.8% Triton X in PBS containing diamidinophenylindole (2Mgml-1). exposed to amsacrine in intact monolayers, or after trypsinization and resuspension in fresh medium at low density (Figure lb) . Thus amsacrine resistance in plateauphase cultures reflects a stable adaptive change, presumably related to the observed cytokinetic changes, rather than reflecting changing environmental conditions such as nutrient depletion, low pH or high cell density per se.
The relative sensitivities of exponential and plateau-phase LLTC cultures to amsacrine and CI-921 were compared using 1 h treatments at a range of drug concentrations (Figure 3 ). CI-921 was the more potent of the two drugs, and provided survival curves with less pronounced curvature than did amsacrine. However, both drugs displayed similar selectivity for exponential phase cells, with D37 ratios (plateau/exponential) of 3.1 and 4.0 for amsacrine, and 3.8 and 3.1 for CI-921 in two independent experiments.
The effects of CI-921 and three other cytotoxic agents against exponential and plateau-phase LLTC cultures were also evaluated by exposing trypsinized single-cell suspensions to a range of drug concentrations. CI-921 again demonstrated much greater activity against exponentialphase cultures, as did doxorubicin and nitrogen mustard (Figure 4 , panels a-c). In contrast, chlorambucil was equally active against cells from both exponential and plateau-phase cultures (Figure 4, panel d) .
Loss of resistance to CI-921 during culture of LLTC cells explantedfrom advanced tumours The effect of amsacrine and CI-921 on the clonogenicity of LLTC cells was investigated immediately after preparing cells from a subcutaneous tumour and also after growing these cells for 1 to 4 days in culture (Figures 5a, b) . Cultures were initiated at 104 and 3 x 105 cellsml-1. After 66h incubation, cells were exposed to cytotoxic agents for one hour prior to trypsinization. Surviving fractions are normalized with respect to control plating efficiencies which were in the range 64-70%.
Cells prepared freshly from a tumour contained a substantial proportion of cells (-10%) highly resistant to amsacrine and CI-921. However, if cells were first cultured for 1 day and then treated with either drug, the surviving fraction decreased by up to one hundredfold. It is unlikely that such sensitivity is due to cumulative damage resulting from pronase and trypsin treatments one day apart, as an even greater increase in sensitivity was observed when the cells were established at a lower density and cultured for 4 days prior to amsacrine or CI-921 exposure (Figure 5a, b) .
This large increase in sensitivity was accompanied by an altered cell cycle distribution. The proportion of cells with a greater than G1 phase DNA content was determined by flow cytometry, and found to increase from 30% at the time of extirpation to over 60% after 1 day in culture (Figure 6 ) and 50% after 4 days.
Effect of tumour size on sensitivity of cells to CI-921
To investigate whether cells undergo changes in sensitivity to CI-921 during tumour growth, LLTC cells (106 per mouse) were inoculated s.c. into B6D2F1 mice either 29 or 20 days prior to sacrifice. Two 29-day tumours (0.99 and 0.94g) and two 20-day tumours (0.09 and 0.27 g) were excised and disaggregated. Cell suspensions derived from the two smaller tumours were more sensitive than those from the larger tumours at each of the three CI-921 concentrations tested (Figure 7 ). Thus as tumour size increases, cells encounter changing environmental conditions which cause them to become progressively more refractory to CI-921. However, differences in the cell cycle distribution of the single cell suspensions from these tumours were not detectable by flow cytometry analysis (data not shown). (Figure 8a ). In contrast to this, chlorambucil ( Figure 8b ) and activated cyclophosphamide (Figure 8c ) showed no such discrimination. 
Discussion
This study has made use of two complementary approaches to investigate the relationship between cytokinetic activity and drug sensitivity in a subline of the Lewis lung carcinoma, LLTC. The first approach, a comparison of the drug sensitivity of exponential and plateau-phase cultures, is similar to many studies which have documented the relative resistance of plateau-phase cultures to a variety of cytotoxic agents. The second approach investigates changes in drug sensitivity under conditions where LLTC cells which have entered a non-cycling state in advanced tumours are recruited into cycle in culture. Cultured LLTC cells Initial studies with the in vitro passaged cell line demonstrate that in unfed plateau-phase cultures most LLTC cells enter a non-cycling state (Figures la, 2 ) in which they become resistant to amsacrine (Figure lb) . This loss of sensitivity is not a consequence of environmental conditions in plateauphase cultures since similar results were obtained on dilution of cells into fresh medium at low cell density immediately before drug exposure (Figure lb) and is in agreement with similar studies with V79 (Wilson et al., 198 la, b) or CHO Chinese hamster fibroblasts (Sullivan et al., 1986) and LoVo human colon carcinoma cells (Drewinko et al., 1981) .
Exponential and plateau-phase LLTC cultures were also used to compare the sensitivites of cycling and non-cycling LLTC cells to the amsacrine analogue CI-921, a new anilinoacridine antitumour drug with high therapeutic activity against Lewis lung tumours (Baguley et al., 1984) . The relative inactivity of amsacrine against solid tumours has been suggested to result, at least in part, from its lack of activity against non-cycling cells (Wilson et al., 198 la, b) . Although CI-921 was more cytotoxic than amsacrine at equivalent doses against both exponential and plateau-phase LLTC cells, the differential was similar for both agents (Figure 3) . Thus the therapeutic superiority of the new amsacrine analogue against Lewis lung tumours does not appear to reflect a lack of discrimination between cycling and non-cycling cells.
One difficulty in the use of LLTC cells for these experiments appears to be the variability in sensitivity to Figures  3b and 4a differ, the relevant point is that the D37 ratios for cycling and non-cycling cells are similar.
The other intercalating agent studied, doxorubicin, also shows higher activity against exponential than against plateau-phase cultures (Figure 4b ), as has been demonstrated with EMT6 (Twentyman & Bleehen, 1975; Kwok & Twentyman, 1985) , CHO (Barranco & Novak, 1974) , L1210 (Bhuyan et al., 1977) and LoVo (Drewinko et al., 1981) cells. Such cycle selectivity of intercalating drugs appears to reflect the activity of topoisomerase II, which declines in noncycling cells (Sullivan et al., 1986) . As examples of a different class of cytotoxic drug two alkylating agents, nitrogen mustard and chlorambucil, have been examined. Byfield and Calabro-Jones (1981) suggested that alkylating agents show selectivity for cycling cells if they are transported into cells by carrier-dependent mechanisms with diminished activity in non-cycling cells. Nitrogen mustard appears to be an example since it is taken up by cells via the choline transport system (Goldenberg et al., 1971; Goldenberg & Sinha, 1973) , the activity of which may decline in non-cycling cells (Goldenberg & Begleiter, 1980) . Similarly, cell proliferation-dependent uptake and cytotoxicity of melphalan have been described (Blosmanis et al., 1987) . We have shown that nitrogen mustard is selectively toxic to exponential-phase LLTC cultures (Figure 4c ), as previously reported for EMT6 cells (Twentyman & Bleehen, 1975; Kwok & Twentyman, 1985) . In contrast chlorambucil, which probably enters cells passively (Goldenberg & Begleiter, 1980 ) is equally active against exponential and plateau-phase LLTC (Figure 4d ).
LLTC cells from tumours
The LLTC cell line possesses several features which make it ideally suited for investigating the drug resistance of cells which enter a non-cycling state in solid tumours. Firstly, subcutaneous tumours of the LLTC line, contain a high proportion of cells arrested in GI/Go phase. Such tumours have a lower growth fraction than the parent Lewis lung tumour (Baguley et al., 1986 , see also Figure 6 ). Secondly, LLTC tumours are dissociated by pronase digestion to give excellent single cell suspensions in high yield (1-2 x 108 cellsg-1). The median volume of these large tumour cells was measured at 2.25 pl by Coulter pulse height analysis (data not shown), implying a packed cell density of about 4x 108 cells g-1. Since histological examination of these tumours revealed many blood-filled sinusoids and areas of necrosis, the above cell yields imply that a high proportion of viable tumour cells are recovered. Thirdly, high plating efficiencies are obtained (mean plating efficiency 58%, range 36-84%). The properties of high recovery and plating efficiency give confidence that all major populations in the tumour are represented in the survival curve data.
Cells from either rapidly growing tumours or nonproliferating plateau-phase cultures possess populations (some 1-10% of the cells) which are resistant to amsacrine, , and doxorubicin at concentrations of 15, 10 and 5 gM respectively (compare Figures 3, 4a, b with Figures 5, 7) .
Such resistance is apparent even in cells from the smallest tumours investigated (0.1 g nodules), and becomes more pronounced as tumour size increases (Figure 7 ) presumably due to intensification of growth-limiting conditions, although cytokinetic differences between tumours of different size could not be detected by flow cytometry means.
The relative sensitivities of cells from tumours before and after culture are similar to the relative sensitivities of quiescent and cycling cells maintained solely in vitro. When cells from either plateau-phase cultures or tumours are cultured under conditions permitting growth, they undergo a large increase in sensitivity to intercalating drugs (Figures 3, 4a and b, 5) , and to nitrogen mustard (Figures 4c, 8a ). In neither case is there an increase in sensitivity to chlorambucil (Figures 4d, 8b) . Moreover, Begg et al. (1985) described conditions under which plateau-phase and proliferating cells in culture are equally sensitive to activated cyclophosphamide, a finding which appears to be true also for tumour-derived cells before and after culture (Figure 8c ).
When cells from tumours are cultured, they are recruited into cycle over the first day with a considerable degree of synchrony, as evinced by the high proportion of S + G2-phase cells (Figure 6 ). When such cells are cultured at a 10-fold lower density, and incubated for four days, they are also in an exponentially growing state, but have lost synchrony. Thus their flow cytometric profile is like that for exponentially-growing LLTC cells passaged in vitro (see Figure 2a ). Under these conditions, the cells are more sensitive to intercalators ( Figure 5 ) and nitrogen mustard (Figure 8a ) than after one day in culture. It must be concluded that (a) the rapid acquisition of drug sensitivity which develops in tumour-derived cells cultured for one day is not a simple consequence of either cell cycle synchronization or protease-mediated cell damage, as the sensitivity continues to develop over several days; (b) tumour-derived cells are heterogeneous with respect to the rate at which they acquire sensitivity to intercalators ( Figure 5 ). Thus cells cultured for 4 days not only manifest reduced survival at all drug concentrations relative to the 1 day cultures, but the survival curves show much less curvature, indicating the disappearance of minor, resistant subpopulations. Indeed, the survival curves of tumour-derived cells cultured for 4 days are of a similar shape (simple exponential) to those of cells released into proliferation by subculture of plateauphase cultures (Figure 4a,b) . This indicates that cells from tumours manifest a heterogeneity of kinetics of re-entry into cell cycle which is not modelled by subculturing the homogeneous populations constituting early plateau-phase cultures.
In summary, plateau-phase cultures contain cells broadly like those recovered from subcutaneous tumours, although the former may not take account of numerically minor (but potentially, therapeutically important) populations present in the latter.
